Stock analysts at HC Wainright set a $65.00 price objective on shares of Seattle Genetics (NASDAQ:SGEN) stock in a report issued on Tuesday. The firm currently has a a “buy” rating on the stock.
In other Seattle Genetics news, Director Felix Baker purchased 950,886 shares of Seattle Genetics stock in a transaction that occurred on Thursday, May 21st. The shares were purchased at an average price of $42.49 per share, for a total transaction of $40,403,146.14. The purchase was disclosed in a document filed with the SEC....
Perhaps, then, "CD30 Cell Depletion Therapy" might be more descriptively accurate......with the serum level of soluble CD30 being the related possible bio-marker of effect.
Of course, SGEN's ADC theoretically offers a much simpler " right off the shelf" therapy addressing of the basic pathophysiology as compared to a CAR T cell approach.
The following statement is absolute TOTAL speculation........... but, the addressable total population of such "potential" therapies in auto-immune and inflammatory disorders is logarithmic relative to HD alone.
Disclosure and warning: Ricardo has lost it. The above could be reality or fantasy......for Ricardo that line between the two is very thin indeed. Do not, repeat , do not base any investment decisions on the above ramblings of this individual.
Ricardo would like to add, at this time, a term to the medical therapeutic lexicon. It is, "CD30 Depletion Therapy".
It references the treatment of autoimmune and inflammatory disease states with agents that deplete CD30+ lymphocytes.
My question is: Has Ricardo gone totally bonkers? Is there hope for him......and, importantly, do you feel that this new term will ever find its way, in the future, into the established language of therapeutic medicine?
Best of luck to all !
Disclosure: Ricardo has a humongous long term position in the shares of SGEN. His opinions are, therefore, to be considered as totally biased. Listen to him only at your own peril. OK, you get the picture.